Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma

INTRODUCTION: Combined anti‐cytotoxic‐T‐lymphocyte antigen 4 and programmed cell death 1 blockade induced high rates of immune‐related adverse events in patients with renal cell carcinoma. However, the safety of reinitiating anti‐programmed cell death 1 monotherapy for patients who discontinued comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Maegawa, Yoko, Kato, Taigo, Fukuhara, Shinichiro, Kiuchi, Hiroshi, Imamura, Ryoichi, Uemura, Motohide, Nonomura, Norio, Fujita, Kazutoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469840/
https://www.ncbi.nlm.nih.gov/pubmed/32914066
http://dx.doi.org/10.1002/iju5.12173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7469840/
https://www.ncbi.nlm.nih.gov/pubmed/32914066
http://dx.doi.org/10.1002/iju5.12173

Ejemplares similares